Cargando…

Optimal management of renal cell carcinoma in the elderly: a review

Both the aging population and the incidence of renal cell carcinoma (RCC) are growing, making the question of tumor management in the elderly a real challenge. Doctors should be aware of the importance of assessing this specific subpopulation. An aggressive therapeutic approach may be balanced by th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quivy, Amandine, Daste, Amaury, Harbaoui, Asma, Duc, Sophie, Bernhard, Jean-Christophe, Gross-Goupil, Marine, Ravaud, Alain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632583/ https://www.ncbi.nlm.nih.gov/pubmed/23626463 http://dx.doi.org/10.2147/CIA.S30765

Ejemplares similares

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma
por: Gross-Goupil, Marine, et al.
Publicado: (2013)

Adaptation of multidisciplinary meeting decisions in a medical oncology department during the COVID epidemic in a less affected region of France: a prospective analysis from Bordeaux University Hospital
por: Heraudet, Luc, et al.
Publicado: (2020)

Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response
por: Teyssonneau, Diego, et al.
Publicado: (2017)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
por: Iaxx, Romain, et al.
Publicado: (2022)

Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade
por: Larroquette, Mathieu, et al.
Publicado: (2022)

Feasibility of robotic-assisted partial nephrectomy for complete remission of metastatic renal cell carcinoma after long exposure to immune checkpoint inhibitors (UroCCR-106)
por: Mebroukine, Samy, et al.
Publicado: (2022)

Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?
por: Granet-Vaissiere, Estelle, et al.
Publicado: (2023)

Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
por: Gross-Goupil, Marine, et al.
Publicado: (2012)

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
por: Vano, Yann-Alexandre, et al.
Publicado: (2021)

Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience
por: Gonnet, Alexis, et al.
Publicado: (2019)

Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non‐small cell lung cancer: A retrospective study
por: Heraudet, Luc, et al.
Publicado: (2022)

Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma
por: de Vries-Brilland, Manon, et al.
Publicado: (2023)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
por: Cho, Byoung Chul, et al.
Publicado: (2020)

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
por: Ladouceur, Alexandra, et al.
Publicado: (2023)

Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression
por: Cooley, Lindsay S., et al.
Publicado: (2021)

Optimal management of breast cancer in the elderly patient: current perspectives
por: Le Saux, Olivia, et al.
Publicado: (2015)

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma
por: Oudard, Stephane, et al.
Publicado: (2021)

Adapted or Adaptable: How to Manage Entropy Production?
por: Goupil, Christophe, et al.
Publicado: (2019)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients
por: Ouzaid, Idir, et al.
Publicado: (2020)

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis
por: Elaidi, Reza, et al.
Publicado: (2020)

Trichloroethylene exposure and somatic mutations of the VHL gene in patients with Renal Cell Carcinoma
por: Charbotel, Barbara, et al.
Publicado: (2007)

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
por: Guigay, Joël, et al.
Publicado: (2021)

Manual de investigación en ciencias sociales
por: Quivy, Raymond
Publicado: (1992)

Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study
por: Vienne, Agathe, et al.
Publicado: (2023)

Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
por: Chevalier, Thomas, et al.
Publicado: (2021)

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2018)

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2018)

Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial
por: Motzer, Robert J., et al.
Publicado: (2022)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Establishment of a replication fork barrier following induction of DNA binding in mammalian cells
por: Beuzer, Paolo, et al.
Publicado: (2014)

Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors
por: Tran, Bao-Tram Thi, et al.
Publicado: (2022)

Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
por: Farace, F, et al.
Publicado: (2011)

Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma
por: Chen, Frank, et al.
Publicado: (2015)

Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2021)

Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients
por: Roubaud, Guilhem, et al.
Publicado: (2015)

An Unusual Initial Presentation of Lupus Nephritis as a Renal Mass
por: Goupil, Remi, et al.
Publicado: (2015)

Optimal management of hypertension in elderly patients
por: Acelajado, Maria Czarina
Publicado: (2010)

Optimal managements of elderly patients with glioblastoma
por: Arakawa, Yoshiki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6uuvde1m1mejpe7gh85cqg2ngt